WO1998052615A9 - Controlling immune response to specific antigens - Google Patents
Controlling immune response to specific antigensInfo
- Publication number
- WO1998052615A9 WO1998052615A9 PCT/US1998/010381 US9810381W WO9852615A9 WO 1998052615 A9 WO1998052615 A9 WO 1998052615A9 US 9810381 W US9810381 W US 9810381W WO 9852615 A9 WO9852615 A9 WO 9852615A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- ligand
- cells
- gene
- cell
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 79
- 108091007433 antigens Proteins 0.000 title claims abstract description 79
- 102000036639 antigens Human genes 0.000 title claims abstract description 79
- 230000028993 immune response Effects 0.000 title abstract description 31
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims abstract description 195
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims abstract description 188
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 152
- 239000013598 vector Substances 0.000 claims abstract description 141
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 129
- 230000014509 gene expression Effects 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 84
- 238000001415 gene therapy Methods 0.000 claims abstract description 47
- 108700019146 Transgenes Proteins 0.000 claims abstract description 42
- 239000013603 viral vector Substances 0.000 claims abstract description 39
- 241000700605 Viruses Species 0.000 claims abstract description 38
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 11
- 230000003612 virological effect Effects 0.000 claims abstract description 10
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 163
- 239000003446 ligand Substances 0.000 claims description 82
- 230000006907 apoptotic process Effects 0.000 claims description 79
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 101150064015 FAS gene Proteins 0.000 claims description 50
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 49
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 49
- 210000001519 tissue Anatomy 0.000 claims description 29
- 238000001727 in vivo Methods 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 17
- 230000001939 inductive effect Effects 0.000 claims description 16
- 210000004185 liver Anatomy 0.000 claims description 15
- 230000002950 deficient Effects 0.000 claims description 12
- 230000010076 replication Effects 0.000 claims description 12
- 239000003623 enhancer Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 241001529936 Murinae Species 0.000 claims description 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 8
- 230000006058 immune tolerance Effects 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 108010054218 Factor VIII Proteins 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 102000001690 Factor VIII Human genes 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 102000010170 Death domains Human genes 0.000 claims description 5
- 108050001718 Death domains Proteins 0.000 claims description 5
- 102000001398 Granzyme Human genes 0.000 claims description 5
- 108060005986 Granzyme Proteins 0.000 claims description 5
- 239000002299 complementary DNA Substances 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 230000007246 mechanism Effects 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 101000802894 Dendroaspis angusticeps Fasciculin-2 Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract description 96
- 238000004519 manufacturing process Methods 0.000 abstract description 19
- 230000001404 mediated effect Effects 0.000 abstract description 19
- 230000004044 response Effects 0.000 abstract description 19
- 230000003247 decreasing effect Effects 0.000 abstract description 16
- 230000005867 T cell response Effects 0.000 abstract description 14
- 230000002035 prolonged effect Effects 0.000 abstract description 14
- 230000024664 tolerance induction Effects 0.000 abstract description 14
- 210000000952 spleen Anatomy 0.000 abstract description 13
- 241000701022 Cytomegalovirus Species 0.000 abstract description 12
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 8
- 230000002093 peripheral effect Effects 0.000 abstract description 7
- 230000000638 stimulation Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 3
- 238000002203 pretreatment Methods 0.000 abstract description 2
- 238000011081 inoculation Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 132
- 210000002540 macrophage Anatomy 0.000 description 35
- 102100032920 Chromobox protein homolog 2 Human genes 0.000 description 20
- 230000006698 induction Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 18
- 108091008874 T cell receptors Proteins 0.000 description 16
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 16
- 210000000987 immune system Anatomy 0.000 description 15
- 210000004989 spleen cell Anatomy 0.000 description 15
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000013605 shuttle vector Substances 0.000 description 14
- 230000009261 transgenic effect Effects 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 108010005774 beta-Galactosidase Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 230000003393 splenic effect Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 102100037850 Interferon gamma Human genes 0.000 description 9
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 230000010415 tropism Effects 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 108010031099 Mannose Receptor Proteins 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 208000003322 Coinfection Diseases 0.000 description 7
- 108010039918 Polylysine Proteins 0.000 description 7
- 102000005936 beta-Galactosidase Human genes 0.000 description 7
- 230000007402 cytotoxic response Effects 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 210000004153 islets of langerhan Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920000656 polylysine Polymers 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 6
- 239000011651 chromium Substances 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000006882 induction of apoptosis Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 101710094396 Hexon protein Proteins 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 101150066555 lacZ gene Proteins 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000006472 autoimmune response Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004073 interleukin-2 production Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108700026758 Adenovirus hexon capsid Proteins 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102100029855 Caspase-3 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 108010006025 bovine growth hormone Proteins 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 229960000301 factor viii Drugs 0.000 description 3
- 108010052621 fas Receptor Proteins 0.000 description 3
- 102000018823 fas Receptor Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000015212 Fas Ligand Protein Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 101710145505 Fiber protein Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000033540 T cell apoptotic process Effects 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229960002963 ganciclovir Drugs 0.000 description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- HWLANCVZPRATJR-GKEYINFOSA-N (3s)-3-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HWLANCVZPRATJR-GKEYINFOSA-N 0.000 description 1
- ZMZRKOASUWINDA-VEABSNGSSA-N (4s)-4-[[(2s)-2-amino-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O ZMZRKOASUWINDA-VEABSNGSSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101150029409 CFTR gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 108010030317 Macrophage-1 Antigen Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 1
- 101000638240 Mus musculus Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 101800000859 Tumor necrosis factor ligand superfamily member 6, soluble form Proteins 0.000 description 1
- 102400000084 Tumor necrosis factor ligand superfamily member 6, soluble form Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000017488 activation-induced cell death of T cell Effects 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003263 anti-adenoviral effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010051758 aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000004651 endocytosis pathway Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 101150082998 pi gene Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 108010010386 tyrosyl-valyl-alanyl-aspartal Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
Definitions
- This invention relates generally to gene therapy. More specifically, the invention relates to suppressing immune system response to antigens expressed on an infected host cell.
- T-cells are one component of the immune system. T-cells can become activated to specific antigens, and function to directly destroy materials which display that antigen, and they also function to sensitize other components of the immune system to the presence of that antigen. While a properly functioning immune system is vital to the health of an organism, in some instances there is a need for the selective inhibition of an immune response to particular materials.
- viral vectors such as adenovirus
- adenovirus are employed in genetic therapies to introduce genetic material and products into an organism.
- One problem encountered with the use of such viral vectors is that they can provoke an immune response in the organism.
- This immune response can destroy the viral vector, and those host cells which are intentionally infected by the vector, as well as therapeutic gene products produced by the action of the vector. Furthermore, immune system "memory" provides a lasting response to this vector; hence, readministration of the material will be ineffective. Therefore, there is a need for a method whereby the immune response to a selected viral vector may be blocked or destroyed. Suppression of immune response is also desirable in the instances of autoimmune disease. As is known, such disease results when the immune system of an organism inappropriately recognizes an organ or tissue of that organism as being foreign, and commences an immune response against it. If this immune response can be blocked, the autoimmune disease can be controlled. Immune suppression is also needed in those instances where organs are transplanted.
- Immune system suppressing drugs are sometimes employed in the foregoing situations; however, such drugs produce a generalized suppression of the immune system, which leaves a patient open to a number of infections. It would therefore be advantageous if immune response to a specific antigen could be suppressed and/or an immune suppressed zone of tissue created within an organism.
- Gene therapy is limited by induction of an immune response to the virus or the gene-therapy protein product (1-4).
- a specific T-cell response to the viral vector usually results the failure of re-expression of transgene (5-6).
- Many efforts have been made to reduce the T-cell response to the viral vector during gene therapy, including the blockade of MHC class I and II antigen, reduce the antigenicity of the viral vector, and prevention of co-stimulation of T-cells (1,7- 11).
- Cytokine and cytokine ligand mediated apoptosis has been shown to be an important pathway for activation-induced cell death in T-cells (16-17).
- T-cell activation leads to upregulation of cytokine ligand and cytokine apoptosis signaling (18,19).
- Activated macrophages express increased levels of cytokine 2 lgs
- Ad5 vectors ligand and mediate apoptosis in the T-cells during antigen presentation, which has been thought to be a critical mean of down-modulating T-cell response (20,21).
- the efficiency of adenovirus-mediated gene transfer has been found to be far superior to other methods for the treatment of heart, lung, and liver disease, and is capable of producing more recombinant protein (22,23).
- the cell-mediated immune response to El a-E3 -deleted adenoviral (Ad5) vector and the limited distribution of reporter gene expression suggest that less immunogenic recombinant vectors and more homogeneous administration methods are required before Ad5 vectors can be used successfully for phenotypic modulation.
- Neonatal intrathymic injection of the vector was able to induce long- term LacZ expression for more than 2 months after heart injection, although neutralizing as well as anti- ⁇ -Gal antibodies were detected in the sera of the animals (24).
- Pretreatment with the anti-TCR monoclonal antibody (mAb) H57 resulted in a significant reduction in lymphocytic infiltration and a prolongation of transgene expression (25).
- Studies with adenoviral vectors show that immune responses limit the efficacy and persistence of gene expression. HSVtk/ganciclovir therapy was more effective in nude rats and immunosuppressed Fischer rats than in immunocompetent Fischer rats (26).
- Adenoviral transgene expression was transient in the thymus of immunocompetent mice but persistent in CD8 + T-cell-deficient and severe combined immunodeficiency (SCID) mice, implicating a role for cytotoxic T lymphocytes in viral clearance (27).
- SCID severe combined immunodeficiency
- Ad5 vector expressing the lacZ transgene upon delivery intra-articularly (5 x 10 8 p.f.u.), lacZ expression was observed in the articular synovium for at least
- Second-generation adenovirus for CFTR gene was evaluated after transfer to baboon lung. This second-generation virus is deleted of El and contains a temperature-sensitive mutation in the E2a gene, which encodes a defective DNA-binding protein. Using a second-generation adenovirus, recombinant gene stability was prolonged and associated with a diminished level of perivascular inflammation as compared to first-generation vectors (29). These data suggest that second-generation adenoviral vectors provide an improved gene delivery vehicle and are useful in gene therapy for diseases such as cystic fibrosis.
- Another mechanism of tolerance is the use of immune privileged sites. This tolerance makes use of the natural occurrence of immune privileged sites which has more recently been thought to be due to production of Fas ligand in subsequent killing of T-cells that may develop and react with antigens within these sites. Installation of adenovirus into these sites results in tolerance to adenovirus and its transgene product. This has been tested using El deleted adenovirus injected into this subretinal space which resulted in minimal cellular and humeral immune response (32). The pancreatic islet may also be an immune privileged sites since murine pancreatic islets injected ex-vivo with Ad5 resulted in high level of beta galactosidase for at least 20 weeks after re-implantation (33).
- Adenovirus mediated gene transfer in adult mouse islets does not impair insulin secretion by the islets (34).
- Ad lacZ injected subretinally resulted in prolonged gene expression, which was equivalent to that observed in either nude mice or after treatment with CTLA4Ig (8).
- the present invention is more widely applicable since transgene expression is not restricted to immune privileged sites.
- antigen presenting cells that express apoptosis inducing ligands and processed viral vector antigens are utilized to directly induce apoptosis of T-cells expressing the ligand receptor resulting in vector-specific T-cell tolerance.
- High levels of ligand and vector antigens are induced in APCs by co-infection.
- Fas ligand FasL
- AdLoxpFasL+AxCANCre pre-treatment of recipient mice with the adenovirus-infected APCs that express Fas ligand resulted in induction of T-cell tolerance to the adenovirus.
- T-cell response to the viral vector is demonstrated by decreased cytokine production, decreased cytotoxic T-cell response, inhibition of clonal expansion of CD3+ T- cells, and prolonged the expression of a marker transgene.
- Induction of T-cell tolerance to adenovirus requires expression of FasL on the APCs, and does not occur with adenovirus infected control APCs.
- T-cell tolerance also requires expression of Fas on the T-cells of recipient mice, since lpr/lpr mice are not tolerized.
- the T-cell tolerance is virus antigen-specific as there is normal T-cell response to mouse cytomegalovirus (CMV) in tolerized mice.
- the instant invention includes a method for promoting immunotolerance in a host to a gene therapy vector, including transfecting a host cell with the vector, such that the vector expresses a transgene, an antigen and a ligand. Expression of the ligand induces apoptosis in a T-cell that is raised against the antigen.
- the instant invention also includes a method for creating an immune privileged site in a tissue of an organism, the method including providing a gene therapy vector encoding and capable of expressing a ligand, a transgene and an antigen and infecting cells of the tissue with the vector.
- the expression of the ligand in the tissue thereby induces apoptosis in T-cells raised against the ligand so as to confer specific immunity to infected cells.
- the instant invention also teaches a gene therapy viral vector that includes a transgene, an apoptosis ligand gene and a gene expression control means for directing product synthesis of said transgene and said ligand gene.
- a gene therapy viral vector that includes a transgene, an apoptosis ligand gene and a gene expression control means for directing product synthesis of said transgene and said ligand gene.
- the use of such a vector for a gene therapy application is detailed.
- the instant invention also discloses a gene therapy viral vector including a transgene, a viral vector gene that is expressed as an antigen on an infected host cell, a functional equivalent of a Fas ligand gene and a gene expression control means for directing product synthesis of said transgene and said Fas ligand gene.
- Figure 1 A schematic illustrating a production method of gene therapy viral vector to inhibit an immune response to viral vector antigens and methods of using the same to produce immune privileged transduced mammalian host cells.
- FIG. 1 Co-infection of APCs with AdloxpFasL + AxCanCre (APC-AdFasL) results in high levels of FasL capable of inducing apoptosis of A20 target cells.
- the AdLoxpFasL is infected into APCs from lpr/lpr mice with and without AxCANCre.
- the APCs are also electroporation transfected with pcDNA3FasL and stimulated with lipopolysaccharide (LPS) (1 ug/ml). FasL expression is determined by ability of the transfected APCs to induce apoptosis of a 51 Cr labeled, Fas sensitive cell line
- mice Ten-week-old C57BL/6-+/+ mice are treated with 1 x 106 of the APCs co-infected with AdLoxpFasL plus AxCANCre (APC-AdFasL) or APCs co-infected with AdLoxpFasL plus AdCMVGFP (APC-AdControl) or PBS every 3 days for 5 doses.
- mice After induction of T-cell tolerance, mice are intravenously inoculated with 1010 Ad/LacZ.
- LacZ gene expression in the liver is analyzed by a quantitative assay (a) and In situ LacZ histochemical staining (b). The error bars indicate the mean ⁇ SEM for 3 mice analyzed separately in triplicate assay.
- FIG. 4 Induction of tolerance to adenovirus by APC-AdFasL.
- Ten-week-old C57BL/6-+/+ mice are injected intravenously with 1 x 106 APC-AdFasL, APC-AdControl or with PBS every 3 days for 5 doses as described above.
- mice are challenged with AdCMVlacZ and T-cell cytotoxic response against APC + adenovirus is determined by killing of the APC cells infected with AdCMVGFP (5 pfu/cell). The percentages of viable GFP expressing APC cells are quantitated by FACS analysis. The error bars indicate the mean ⁇ SEM for 3 mice analyzed separately in triplicate assays.
- FIG. 1 Decreased IFN-gamma and IL-2 induction by spleen cells from tolerized B6 +/+ mice. 10 6 of the APC-AdFasL or APC-AdControl cells were transferred to B6 +/+ mice. The spleen cells were incubated for 24 hours with
- APCs that were uninfected, or infected with adenovirus, and irratiated.
- Levels of IL-2(A) and IFN- ⁇ (B) in the supernatant was determined by ELISA.
- APC-AdFasL or APC-AdControl cells are transferred to B6 +/+ mice.
- the spleen cells are incubated for 24 hours with APCs that were uninfected, or infected with adenovirus, and irratiated.
- Levels of IL-2 in the supernatant is determined by ELISA.
- FIG. 7 IFN-gamma induction by spleen cells from B6 Ipr/lpr mice. 10 6 of the Ipr APC-AdFasL or APC-AdControl cells are transferred to B6-lpr/lpr mice. The spleen cells were incubated for 24 hours with APCs that are uninfected, or infected with adenovirus, and irratiated. Levels of IFN- ⁇ in the supernatant is determined by ELISA.
- Figure 8. Ad/FasL APCs induces specific T-cell tolerance to adenovirus.
- mice/group are treated with either C57BL/6-+/+ mice (5 mice/group) are treated with APC-AdFasL or APC-AdControl (M ⁇ -CV).
- mice are challenged in vivo with either AdCMVLacZ or mouse cytomegalovirus (MCMV).
- MCMV mouse cytomegalovirus
- splenic T-cells are stimulated in vitro with APCs alone, or APCs infected with MCMV or AdCMVLacZ.
- IL-2 production in the supernatants was determined by ELISA 48 hours later.
- FIGS 9a-9e Characterization of Fas ligand expressing APCs.
- Peritoneal resident macrophages from B6-lpr/lpr mice are isolated and cultured in RPMI- 1640-12% FCS. After short-term culture, growing macrophages are tested for MHC and B7 expression, (a)-(c) 1 x 10 6 macrophages are stained with biotin- co ⁇ jugated anti-H-2D b , anti-IA b (PharMingen) or CTLA4-Ig (Dr. Linsley: Bristol- Myers Squibb), followed by FITC-conjugated streptavidin (Southern
- Macrophages are tranfected with a pcDNAIII expression vector (Invitrogen) containing a full length murine Fas ligand cDNA, or empty vector, using a standard DEAE-Dextran method. Transfected macrophages are selected with 0.5 mg/ml of G418 (Sigma).
- the selected macrophages are mixed with [ 51 C]r-labeled, Fas ligand sensitive A20 cells at the indicated ratios and, after an 8 h incubation, the specific release is determined, (e)
- the splenic T-cells are purified from 4-wk-old MRL/MpJ-+/+ and MRL/MpJ-lpr/lpr mice (Jackson Laboratory) using a T-cell enrichment column (R&D Systems).
- 5 x 10 5 purified T-cells are cultured with 5 x 10 4 ⁇ -irradiated macrophages in round-bottom, 96-well plates for 5 d, and proliferation is determined by adding 1 mCi of [ 3 H]-thymidine (Amersham) 16 h prior to harvest.
- APCs 4-wk-old of MRL-+/+ and -Ipr/lpr mice are injected i.v. with macrophages (2 x 10 5 ) transfected with Fas ligand or control vector every 3 d for 6 times.
- splenic T-cells are isolated from treated mice and cultured under various stimulatory conditions, a, 5 x 10 5 T-cells are cultured with 2 x 10 5 ⁇ -irradiated total spleen cells from B6 +/+ mice, b, 5 x 10 5 T-cells are cultured with 2 x 10 5 ⁇ -irradiated total spleen cells from BALB/c mice, c, 5 x 10 5 T-cells are cultured with 5 mg/ml of anti-CD3 antibody.
- T-cell proliferation is determined by incorporation of [ 3 H]-thymidine at indicated time points. The error bars indicate the mean ⁇ SEM for 3 mice analyzed separately in triplicate assays.
- FIG. 11 Antigen-specific clonal deletion of the T-cells induced by Fas ligand expressing APCs in H-2D b HY reactive TCR transgenic mice, (a) Expression of H-2D b is determined as described above and analyzed by flow cytometric analysis, (b) Fas ligand activity is assayed by specific lysis of A20 target cells at the indicated E/T ratio as described in Figure 9. (c) The CD4 CD8 T-cells (2 x 10 6 ) from B6-lpr/lpr female or male mice are injected every 3 d for 3 times into female, TCR transgenic D b /HY -+/+ and -lpr mice.
- T-cells (a) Expression of M33, CD8, and Fas on the T-cells in the PLN is determined by 3-color flow cytometric analysis. 1 x 10 6 total PLN cells are stained with biotin-conjugated M33, then with FITC-conjugated anti-CD8 and PE- conjugated anti-Fas (PharMingen). 10,000 viable lymphocytes were analyzed by FACScan. Two-color contour plots of CD8 and M33 are shown, and the percentage of M33 D8 + T-cells multiplied by the total number of spleen cells. The error bars indicate the mean ⁇ SEM for 3 mice analyzed, (c) Fas expression on the M33 + CD8 + cells. The M33 + CD8 + cells are gated and the histograms of Fas are shown. The percentage of Fas expression on the gated M33 + CD8 + T-cells is indicated.
- NIT-1 cells are transfected with pcDNAIII vector containing Fas ligand gene (NIT-l/FL) or empty vector (NIT-1/Ctl), and selected with G418. Fas ligand activity is measured by a [ 51 Cr] release assay,
- NIT-l/FL pcDNAIII vector containing Fas ligand gene
- NIT-1/Ctl empty vector
- Fas ligand activity is measured by a [ 51 Cr] release assay
- 6-wk-old female NOD mice are i.p. injected with 5 x 10 5 NIT-l/FL or NIT-1/Ctl once.
- Splenic T-cells are isolated
- FIG. 14 Histologic Analysis of Insulitis. 6 wk-old female NOD mice are i.p. injected with 5 x 105 NIT-1/Ctl (A) or NIT-l/FL (B). Mice are sacrificed at 12 week of age. H&E stained paraffin sections of pancreas were examined (400x).
- FIG. 15 Prolonged expression of Ad/Luc in muscle co-transfected with pFasL. Tongue muscle of mice (5 mice/group) were analyzed at different time points for luciferase production. There was increased production of luciferase in muscle cells injected with adenovirus plus FasL compared to muscle injected with adenovirus and control empty vector.
- FIG. 16 Construction of p ⁇ Elsplb/FL and PJM17. Production of p ⁇ Elsplb/FasL. Shown is a 10.5 kb vector that contains Ad from 0 map units to 1 map unit, the CMV promoter, full length Fas ligand and a 0.4 kb SV40 polyA tail. This shuttle vector was combined with the 40.3 kb pJM17 vector containing the adenovirus genome - ⁇ E1 and also contains an origin replication and an ampicillan-resistant site.
- FIG. 17 Production of p ⁇ ElsplBloxp/FasL.
- a 10.4 kb shuttle vector containing the fragment of adenovirus from 0 map unit to 1 map unit is followed by the 0.7 kb CMV promoter. This is followed by 2 LOXP sites separated by a 2 kb stuffer fragment plus a 0.3 kb bovine growth hormone polyA tail.
- the ftill- length 0.9 kb Fas ligand is cloned downstream from the stuffer fragment which is followed by an SV40 PolyA tail and by the 9.8 - 16.1 map units of adenovirus.
- Vectors and methods are providing for introducing a transgene into a host using a virus-based delivery system, the vectors and methods designed to inhibit the host immune system from interfering with the specific gene therapy vector.
- the present invention incorporates the production of apoptosis inducing ligands into antigen presenting cells through gene therapy. Normally, a host T-cell directed towards an antigen of a transfected cell encounter an antigen resulting in elimination of expression of the transfecting transgene.
- the present invention promotes immunotolerance towards transfected host cells.
- the term "gene” or "transgene” is a nucleic acid, either naturally occurring or synthetic which encodes a polypeptide product.
- nucleic acid is intended to mean natural or synthetic linear, circular and sequential arrays of nucleotides and nucleosides, e.g. cDNA, genomic DNA, mRNA, and RNA, oligonucleotides, oligonucleosides, and derivatives thereof.
- An apoptosis ligand is any polypeptide cytokine that induces apoptosis or otherwise is lethal to a cell upon complexing the ligand.
- the present invention is detailed with the exemplary naturally occurring ligand, Fas ligand; however, it is appreciated that other known apoptosis ligands are similarly operative.
- ligands illustratively include: Fas ligand 2 which induces apoptosis by acting with death domain region molecules DR3, DR4 and DR5; TNF which induces apoptosis by acting with TNFRI; Granzyme B and porferin which are natural killing molecules associated with T-cells; and antibodies specific to T-cell apoptosis ligand receptors: anti-Fas, anti-DR3, anti-DR4, anti- DR5 and anti-TNFRl.
- Fas ligand 2 which induces apoptosis by acting with death domain region molecules DR3, DR4 and DR5
- TNF which induces apoptosis by acting with TNFRI
- Granzyme B and porferin which are natural killing molecules associated with T-cells
- antibodies specific to T-cell apoptosis ligand receptors anti-Fas, anti-DR3, anti-DR4, anti- DR5 and anti-TNFRl.
- Figure 1 is a schematic illustrating a production method of gene therapy viral vector to inhibit an immune response to viral vector antigens and methods of using the same to produce immune privileged transduced mammalian host cells.
- the method of producing an immune tolerated gene therapy vector of the present invention involves a series of steps. In selecting a virus to be modified by way of the present invention one examines a series of factors including: viral vector tropism, sites of vector expression within a host cell, ease of vector gene manipulation, required duration of expression, pathogenicity and the like.
- the adenovirus (Ad) affords many advantages as a vector as evidenced by its popularity. Ad replicates episomally within a host cell and as such the host cell genome is unaltered resulting in no transgene expression in host cell daughters.
- the adeno-associated virus is a smaller virus than Ad, which is capable of integrating into a host cells chromosomes, thereby affords the option of long-term expression.
- the herpes virus (HV) is trophic for the nervous system of a host and affords the option of transducing cells of the nervous system.
- the upstream regulatory region (URR) of the virus is excised.
- a URR contains at least a promoter which may be regulatable, for example, by TCN or steroids, or inducible, such as in Loxp/Cre system.
- the URR is closed into a shuttle vector plasmid.
- the shuttle vector contains an origin of replication, and an apoptosis ligand gene expression cassette.
- a marker gene, an enhancer, a signal sequence, or a stuffer fragment are included in the plasmid.
- An apoptosis ligand gene or fragment thereof is excised from a source cell line and cloned into an apoptosis ligand gene expression cassette.
- the cassette contains control elements necessary for replication within a host cell such as a promoter, a 5' untranslated region and a polyadenylation sequence.
- the cassette is incorporated into the shuttle vector plasmid so as to stimulate apoptosis ligand expression in concert with reading of the viral URR.
- the shuttle vector plasmid is then combined with a viral vector replication plasmid from with the pathogenic protein encoding genes have been deleted or at least inactivated.
- the combined plasmids form a recombinant for delivering selected portions of the viral genome and an apoptosis ligand for suppressing the immune response to transfected cells presenting viral antigens thereon.
- Figure 1 shows the transgene expression cassette as being incorporated into the vector replication cassette.
- the transgene expression cassette is incorporated into the shuttle vector plasmid.
- the recombinant is then alternatively introduced into a cell culture or into a mammalian host.
- the transfection of a cell culture is carried out by a prior art method (35).
- the transfected cells expressing viral antigens and an apoptosis ligand are identified by methods illustratively including indirect immune fluorescent assay and 51 Cr release assay.
- the transiently transfected antigen presenting cell lines are macrophages or NIT-1 ⁇ islet pancreas cells.
- the present invention is readily extended to be mediated by a cell-cell interaction where the apoptosis ligand is expressed on cell type one which also expresses a different ligand, the different ligand being able to activate a receptor on a second cell type.
- the preferred situation is where the different ligand of cell type one - receptor of the second cell type interaction up-regulates a death domain molecule in the second cell type.
- Cultured cells expressing both the ligand and viral vector antigens are then exposed to T-cells that have been sensitized to the viral vector.
- the immune system challenged transfected cells are then assayed as to proliferation, or cytotoxicity or as to the inducement anti-viral vector antibody production.
- the recombinant is introduced into a mammalian host by a route dictated by the targeted host cells.
- lung tissue to be transfected with CFTR or protease inhibitor so as to treat cystic fibrosis is preferably administered intra- nasally as an aerosol suspension;
- blood to be transfected with Factor 8 so as to treat hemophilia is preferably administered intravenously, intra peritoneally to transfect organ specific diseases of the liver, pancreas, etc., intra marrow for marrow and intra-myocardial for heart tissue
- adjuvants are readily added to a gene therapy vector of the present invention to facilitate administration.
- the host transfected tissues are biopsied or excreted gene product markers associated with the gene therapy are assayed to monitor the efficacy of the therapy. In vitro assays are also applicable to in vivo therapy monitoring.
- the present invention provides for a gene therapy vector capable of delivering a complete apoptosis ligand, as well as smaller functional components of these ligands. Certain truncations of these ligands interact with death domain molecules and thereby induce T-cell apoptosis.
- the nucleic acid sequences coding for Fas ligand, Fas ligand 2, Granzyme B and porferin can be altered by substitutions, additions, deletions or multimeric expression that provide for functionally equivalent ligands. Due to the degeneracy of nucleic acid coding sequences, other sequences which encode substantially the same amino acid sequences as those of the naturally occurring ligands may be used in the practice of the present invention.
- nucleic acid sequences comprising all or portions of the nucleic acid sequences encoding the above ligands, which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change.
- one or more amino acid residues within a sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
- Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
- the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
- the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
- the positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged
- (acidic) amino acids include aspartic acid and glutamic acid.
- ligands or fragments or derivatives thereof which are differentially modified during or after translation, e.g., by glycosolation, protolytic cleavage, linkage to an antibody molecule or other cellular ligands, etc.
- the recombinant ligand encoding nucleic acid sequences of the present invention may be engineered so as to modify processing or expression of a ligand.
- a signal sequence may be inserted upstream of a ligand encoding sequence to permit secretion of the ligand and thereby facilitate apoptosis.
- a ligand encoding nucleic acid sequence can be mutated in vitro or in vivo to create and/or destroy translation, initiation, and/or termination sequences or to create variations in coding regions and/or form new restriction endonuclease sites or destroy pre-existing ones, to facilitate further in vitro modification.
- Any technique for mutagenesis known in the art can be used, including but not limited to in vitro site directed mutagenesis (36), use of Tab linkers (Pharmacea), etc.
- Fas ligand polymorphisms in the intracellular domain modify the hydrophilic regions of the ligand but do not greatly affect Fas ligand function in inducing apoptosis.
- mutations of Fas ligand that do not affect the apoptosis inducing potential of the ligand including additions, substitutions, truncations and the like are recognized to be usable in the present invention.
- a polynucleotide modification of Fas ligand to produce multimers of the Fas ligand is a means of increasing apoptosis potential of the Fas ligand. By extension, the same holds true for other ligands.
- Fas ligand binds to Fas and may impede apoptosis by endocytosis of Fas without inducing apoptosis. Therefore, larger conglomerates of Fas ligand such as surface Fas ligand or Fas ligand that has been engineered to be cross-lined and produced by cells is more affective in the induction of apoptosis than the naturally occurring Fas ligand.
- T-cells which are activated against a specific antigen, are selectively eliminated thereby preventing or reducing immune response to that antigen. T-cells are eliminated by activation-induced cell death of T-cells, which is caused by Fas-mediated apoptosis of those activated T- cells that express Fas and Fas ligand.
- APCs antigen presenting cells
- MHC major histocompatibility complex
- a particular peptide/MHC complex is recognized by the specialized receptor on the surface of a T-cell thereby activating that T-cell.
- Activated T-cells then reproduce, and the offspring proceed to initiate an immune response by attacking those materials displaying the foreign antigen, and by further activating B cells and other components of the immune system.
- some of the activated T-cells persist so as to provide an enhanced response to further infection.
- the Fas ligand can be employed to produce apoptosis of T-cells that express Fas. More specifically, it has been found that introduction of APCs, that express a Fas ligand, into an organism will induce apoptosis of T-cells that express Fas, thereby resulting in antigen specific T-cell tolerance. It has been found that an adenovirus capable of expressing the Fas ligand can be used to transfect macrophages and other APCs. This results in a highly efficient presentation of adenovirus antigens and Fas ligand on the APCs.
- Such APCs will then confer immune tolerance to the adenovirus vector by selectively eliminating those T-cells which are capable of reacting with antigens from the adenovirus vector.
- This novel therapeutic approach greatly enhances the utility of adenoviral based gene therapies by producing specific tolerance to the therapeutic materials. Since the therapy of the present invention is highly selective, adverse affects heretofore encountered with broad immunosuppressive approaches are eliminated.
- adenovirus expressing the Fas ligand
- APCs can be targeted to APCs via the mannose receptors on the APCs.
- APCs can be transfected with Fas, in vitro, and the transfected cells introduced into the organism; or, transfection may occur in vivo, by administration of the adenovirus vector to the organism.
- autoimmune disease occurs when an organism's immune system becomes activated toward tissue of the organism itself. Selective apoptosis of those activated T-cells which cause the autoimmune response will control autoimmune disease. Transfection of those cells which elicit the autoimmune response with the Fas gene will produce syngeneic cells which will induce tolerance to an autoimmune antigen, in T-cells via Fas mediated apoptosis.
- the syngeneic cells may comprise APCs or they may comprise cells of the tissue provoking the autoimmune disease, in which instance these cells will then cause the APCs to present the Fas ligand and the autoimmune antigen.
- These principles are also be employed to produce immune privileged sites within an organism. Provision of an immune privileged site facilitates organ transplant and other such tissue graft procedures. An immune privileged site also prolongs expression of an adenovirus gene product at that site. Creation of the immune privileged site is accomplished by causing cells at the site to produce the
- Fas ligand and the presence of this ligand will protect an adenovirus from immune system attack.
- Production of Fas ligand is accomplished by the virus used for the therapy itself, or by genes introduced into the tissue via another carrier. Fas ligand expression induces specific tolerance by apoptosis. Fas ligand expression is also induced by clonal deletion. Peripheral T-cell tolerance is maintained by activation-induced cell death of the T-cells, which is mediated by Fas-mediated apoptosis of the activated T-cells that express Fas and Fas ligand (37-41). Thus, Fas ligand expression is used to create immune-privileged sites and prevent graft rejection by inducing apoptosis in the T-cells (42-44).
- the instant invention includes a novel immunointervention strategy for adenovirus gene therapy in which Fas ligand gene therapy is used to confer immune privilege. This response is mediated at the cell level and an immune response to cells is prevented by Fas ligand production by these cells.
- the mouse FasL is introduced into the El A site of Ad to produce a recombinant virus which is both replicative defective and expresses high levels of Fas ligand.
- transgene vector inhibits the immune response of the host thereto, resulting in highly efficient presentation of adenovirus antigens and Fas ligand on the macrophages.
- the current results demonstrate that AdLoxpFasL co-infection with AxCANCre results in very high levels of FasL in a majority of infected APCs.
- APCs can express high levels of Fas ligand without undergoing autocrine suicide. This is in contrast to low efficiency transfection of DNA into APCs using lipofectin (l%-5%) or electroporation (8%).
- the present invention utilizes several unique technologies to allow high expressions of Fas ligand plus high expression of process adenovirus antigen on an antigen presenting cell to induce apoptosis of T-cells that react with this antigen.
- the present invention demonstrates extremely efficient inhibition of CD3 T T-cell expansion that are potentially reactive with APC processed adenovirus antigens leading to prolongation of gene expression by challenge after tolerance with AdCMVLacZ.
- High efficiency inhibition of adenovirus-reactive T-cells is achieved by first treatment of mice with 5 dosages of APC-AdFasL using APCs from B6-lpr/lpr mice. After admimstration every three days with 5 dosages, these APCs toleralize to antigens for up to four weeks by inhibition of APC/antigen reactive T-cells.
- AdCMVLacZ (10 10 pfu.) intravenously one week after tolerance does not lead to a significant T-cell response since there is deletion or inhibition of all potentially reactive T-cells.
- the absence of cytotoxic T-cells at 7 days post-infection with AdCMVLacZ correlates with a prolonged expression of LacZ in toleralized mice compared to non-toleralized mice.
- the present invention shows that adenovirus expression Fas ligand within an antigen presenting cell used as pretreatment can be utilized to toleralize against second administration of adenovirus/gene therapy product.
- mice are toleralized with APC-AdFas-L.
- inventive tolerance procedure There are several independently novel features to the inventive tolerance procedure.
- AdCMVLacZ is used to challenge mice, but the LacZ gene is not encoded in the AdLoxpFasL + AxCANCre viruses infecting the toleralizing APCs, since this would require a triple adenovirus infection, with potentially lower infection efficiency. Nevertheless, there is tolerance to readministration of AdCMVLacZ during challenge. AdCMVLacZ elicits an immune response to LacZ as well as adenovirus (46-48). These results indicate that tolerance to adenovirus alone can prolong gene therapy even in the absence of tolerance to one of the more immunogenic transgenes, LacZ.
- Tolerance induction by APCs infected with a viral vector expressing high levels of FasL is specific for the viral vector, but not with an irrelevant virus.
- the present toleralizing technique completely abrogates the ability of responding to the toleralizing virus used to infect the APC, but not to APC infected with an irrelevant virus. Therefore, the present invention for toleralizing to a viral vector gene therapy is widely applicable, does not result in generalizing immune- suppression and is amenable to readministration for repeated treatment without inducing an immune-suppressed state.
- the first approach uses a method to couple the adenovirus fiber/knob to a mannosylated polylysine peptide.
- the modified receptor is targeted to macrophages.
- This technique is used to attach mannosylated polylysine to a modified, replicative defective adenovirus to determine adenovirus redirection to combine with high efficiency to APCs in vivo.
- Another method for APC infection with Ad involves using the adenovirus-polylysine infection technique to deliver adenovirus-polylysine-DNA complexes to accompany gene therapy to targeted cells for cell lines that did not already express Fas ligand. This is advantageous in the creation of immunoprivileged sites in cells that do not express Fas ligand or do not undergo apoptosis after expressing Fas ligand.
- a more stringent test of tolerance induction involves later challenges of the mice in vivo with either the Ad-APC-FL or Ad-APC, as well as control Ad without APC. This subsequent reaction elicits a strong secondary immune response in the mice that were previously immunized with adenovirus, but there is little or no response in mice that have been tolerized with Ad-APC-FL.
- Ad-APC-FL and Ad-APC, or Ad in the subsequent administration determines if Ad-APC-FL is required with each administration of adenovirus for a specific APC, or if the initial induction of tolerance confers long-term tolerance to adenovirus.
- This technique is used to induce tolerance to alloantigens, and that systemic administration of APC-FL does not induce significant toxicity to the liver or long and has no other apparent toxic effect on the mouse.
- FasL by the Ad infected cell to create immune privilege sites.
- Fas-ligand gene therapy is useful as a strategy to prevent immune response to viral vector antigens and in this embodiment of the invention, adenovirus.
- the ability to exploit this strategy is supported by the finding that Fas ligand expression can be targeted to APC in vitro using the polylysine method for targeting Fas ligand and adenovirus. This method promotes targeted gene delivery via the receptor mediator endocytosis pathway (49-53). It is necessary in this approach to link the vector, such as adenovirus to molecular conjugates and, at the same time, preserve both the binding and endosome disruption capabilities of the virus.
- the conjugates are preferably linked through the hexon protein.
- the linkage is accomplished by an antibody bridge through a molecular conjugate and the viral vector. This is accomplished by conjugating a monoclonal antibody against a foreign epitope on the viral vector hexon protein to the polylysine.
- the normal viral tropism of the vector is ablated.
- redirection to macrophages optionally involves the mannosylated fiber-knob (53-57).
- Regulation of the macrophage mannose receptor expression and cloning of the mannose receptor has been carried out (58- 60).
- the first three exons of the mannose receptor gene encode: a signal sequence, the NH 2 -terminal cysteine rich domain, and the fibronectin type II repeat, while the final exons encode the transmembrane anchor and the cytoplasmic tail.
- the intervening 26 exons encode the 8 carbohydrate-recognition domains and intervening spacer elements.
- the mannose receptor is expressed on alveolar macrophages and a highly homologous receptor DEC-205 is expressed on dendritic cells and thymic epithelial cells (58).
- DEC-205 is able to bind carbohydrates and mediate endocytosis. It is rapidly taken up into the coated pits forming vesicles and delivered to a multi-vesicular endosomal compartment that resembles the MHC class Il-containing vesicles.
- the mannose receptor on macrophages and APCs provides an excellent target for modified adenovirus tropism and delivery of genes to APCs.
- the present invention preferably utilizes adenovirus expressing Fas ligand under the regulation of a well characterized target cell lysozyme promoter or a similar target specific promoter to transfect into a target cell (61-63) efficiently present of viral vector antigens and a cytokine ligand on the target cells.
- Example 2 Construct Fas ligand expression adenovirus vector.
- a 10.4 kb shuttle vector containing the fragment of adenovirus from 0 map unit to 1 map unit followed by the 1.6 kb chicken ⁇ -actin promoter plus CMV enhancer. This is followed by 2 Loxp sites separated by a Neo resistant gene plus a 0.3 kb bovine growth hormone poly A tail. The full-length 0.9 kb FasL is cloned down-stream from the bovine growth hormone poly A tail which is followed by an SV40 polyA tail and by the 9.8 - 16.1 map units of adenovirus.
- Example 3 - MCMV Virus Example 3 - MCMV Virus.
- MCMV Virus Smith strain is obtained from the American Type Culture
- the virus are titrated as duplicates in log 10 dilutions on subconfluent primary murine embryo fibroblasts in 12-well plates. Seven days later, monolayers are stained with neutral red and the number of plaques counted.
- the supernatant is dispensed into aliquots, which are stored at -80 °C and used as the MCMV stock virus pool (3xl0 7 PFU/ml).
- Example 4 Infection of antigen presenting cells for Fas ligand expression.
- Murine B6-lpr/lpr APCs are infected with either AdLoxpFasL plus AxCANCre (APC-AdFasL) or
- AdLoxpFasL plus AdCMVGFP (APC-AdControl) at 5 pfu/cell of each viruses for
- Expressed murine FasL and adenoviral antigens on the surface of B6-lpr/lpr APCs are identified using indirect immune fluorescent assay (64) and the killing activity is evaluated by 51 Cr release assay (65).
- Example 5 Analysis of FasL by APCs Infected with AdLoxpFasL plus AxCANCre.
- Fas ligand (FasL) cytotoxicity is assayed as previously described (65).
- FasL expression is determined by ability of the transfected APCs to induce apoptosis of a 5I Cr labeled, Fas sensitive cell line A20.
- Target cells (lxl 0 6 ), which are sensitive to cytotoxic lysis, are incubated with 20 ⁇ Ci of [ 51 Cr]-sodium chromate in 100 ⁇ l of RPMI- 1640 containing 10% FCS at 37 °C for 1 h. After washing with medium, these cells are used as target cells. Effector cells are prepared from B6-lpr/lpr APCs infected with AdLoxpFasL plus AxCANCre as described above.
- effector cells are then incubated with [ 51 Cr]-labeled target cells (lxlO 4 ) at different effector/target (E/T) ratios in a total volume of 200 ⁇ l of the medium. Release of 51 Cr into the supernatant is assessed 6 h later using a ⁇ -counter. The percentage of specific 51 Cr release is calculated as follows:
- Example 6 Administration of APC-AdFasL for induction of tolerance.
- mice Ten-week-old C57BL/6-+/+ mice are injected intravenously with 1 x 10 6 of the APCs co-infected with AdLoxpFasL plus AxCANCre (APC-AdFasL) or
- mice are treated with AdCMVlacZ (lxlO 10 pfu i.v.) or MCMV (1x10 s pfu i.v.). After an additional 7 days, purified splenic T-cells are stimulated in vitro with APCs alone, or APCs that are incubated either with AdCMVlacZ (lxlO 10 pfu i.v.) or MCMV (1x10 s pfu i.v.). After an additional 7 days, purified splenic T-cells are stimulated in vitro with APCs alone, or APCs that are incubated either with
- Example 8 Quantitation of ⁇ -galactosidase expression in liver. ⁇ -galactosidase activity is determined as previously described (66).
- Freshly isolated liver tissue is homogenization for 10 s in a tissumizer in 1 ml of ⁇ -gal buffer (Tropix, Inc., Bedford MA).
- the homogenate is centrifuged at 12,500 x g for 10 min at 4°C, and the supernatant is heated for 60 min at 48 °C to inactivate the endogenous eukaryotic ⁇ -galactosidase activity.
- the sample is then centrifuged at 12,500 x g for 5 min, and 10 ⁇ l of the supernatant is assayed for ⁇ -galactosidase activity using the Galacto-lightTM (Tropix, Inc., Bedford MA) chemi-luminescent reporter assay.
- the reaction is carried out for 10 min at room temperature (RT) and ⁇ -galactosidase activity is assayed using a luminomiter
- the adenovirus shuttle vector construct is produced by cloning the enhanced GFP gene from pCA13 (Clonetech) into the Hindlll-Xbal site. This is cotransfected with pJM17 to produce recombinant AdCMVGFP.
- AdCMVGFP is plaque purified by 3 rounds of selection. These are used to infect APC to be used as target cells for analysis of cytotoxic effector T-cells from mice treated with
- APC AdLoxpFasL+AdCMVGFP
- APC AdLoxpFasL+ AxCANCre
- Effector cells are prepared from spleen, and peripheral lymph nodes of
- Ad-immunized and non-immunized mice are then incubated with AdCMVGFP-infected target cells (lxl 0 5 ) at different effector/target (E/T) ratios in round-bottom microtiter plates in a total volume of 200 ⁇ l of the medium for 48 hours, and Green fluorescent positive APC are sorted using FACS analysis. The percentage of specific cytotoxicity was calculated as follows:
- Example 10 Cytokine production in vitro in response to APC infected with adenovirus.
- B6 Ipr/lpr APCs are infected with AdCMVLacZ (10 pfu/cell) for 1 hour in 1 ml of media and then diluted to additional of 10 ml of RPMI 1640 supplemented with 10% fetal bovine serum. The cells continue to culture at 37 °C for 24 hours. Before as a targeting cells, the APC is ⁇ -irradiated, and lxl 0 5 APC are mixed at different ratios of T-cells isolated from the spleen of tolerized mice.
- the mixed cells are incubated at 96 well plate for 2 days at 37 °C.
- the superaatants are collected and induction of IL2 and interferon gamma are determined using ELISA assay kit (R & D systems Inc., MN).
- Example 11 Histopathological examination of tissue sections.
- Paraffin-embedded tissue sections are deparaffinated and treated with 3%
- DAB diaminobenzidine
- the two-tailed Student's t-test is used for statistical analysis when two different groups of samples are compared.
- Example 14 Co-infection of AdLoxpFasL + AxCANCre results in high levels of FasL capable of inducing apoptosis of A20 target cells.
- the instant invention includes an AdLoxpFasL modified adenovirus to yield high titer production of the virus in 293 cells (45).
- This technique also facilitates control of FasL expression since FasL is not expressed in the absence of co-infection with AxCANCre.
- This technique is used to induce high FasL expression by a APC cell from Fas-mutant B6-lpr/lpr mice which could induce apoptosis of A20 target cells (Fig. 2).
- adenovirus gene therapy in the liver is limited due to an acute inflammatory response and a chronic cytotoxic T-cell response (67).
- AdFasL expressing APCs leads to prolongation of transgene expression delivered by adenoviral vector
- the APC-AdFasL tolerized and APC-AdControl treated mice are inoculated with AdCMVlacZ (lxlO 10 pfu). LacZ gene expression in the liver is kinetically analyzed by quantitative measurement of LacZ protein and histochemistry staining. The levels of LacZ gene expression in the liver rapidly decreased in mice treated with APC-AdControl (Fig. 3 a).
- LacZ expression peaked at day 7 after expression of AdCMVLacZ in both toleralized and non-toleralized mice, and rapidly decreased in non-toleralized mice compared to non-toleralized after day 7.
- mice are toleralized in vivo as described above and challenged with AdCMVLacZ. Seven days after challenge splenic T-cells are purified and used as effect cells at different E/T ratios to kill AdCMVGFP infected APCs. There is a high cytotoxic response by T-cells from mice treated with
- Example 17 T-cell tolerance demonstrated by decreased IFN- ⁇ and IL-2 production in vivo.
- mice are tolerized as above with either APC-AdFasL or APC-AdControl as a control. Thirty days after tolerance induction, mice are sacrificed and spleen cells are stimulated with APC or APC infected with AdCMVlacZ. Non-infected APCs did not stimulate T-cells as determined by low IL-2 ( Figure 5 A) and LFN- ⁇ ( Figure 5B) in the supernate at 24 or 48 hours ( Figure 4). In contrast, there is high production of IL-2 and IFN- ⁇ from spleen cells from C57BL/6 which are tolerized with APC-AdControl, which do not express FasL. B6+/+ mice that are tolerized with APC-AdFasL are tolerized as indicated by low IL-2 ( Figure 5 A) and
- Example 18 Fas Expression by Recipient T-cells is required for tolerance Induction.
- Fas expression in recipient C57BL/6 mice is required for tolerance induction since spleen cells from B6-lpr/lpr mice produced high levels of IFN- ⁇ and IL-2 despite being tolerized with APC-AdFasL (Fig. 6 A, 6B).
- Example 19 Decreased T-cell expansion in APC-AdFasL treated mice.
- mice B6+/+ mice were treated with APC-AdFasL or APC-AdControl every 3 days for 5 doses, and then all treated mice were IN. challenged with AdCMVlacZ (lxlO 10 pfu). Three days later, frozen sections of spleen from naive mice (Fig. 7a), control APC treated mice (Fig. 7b), FasL APC treated mice (Fig. 7c) and were stained with anti-CD3 antibody using a standard ABC technique. There was no expansion of CD3 + T-cells in tolerized mice spleen, whereas mice treated with control APCs resulted in clonal expansion in spleen after challenge.
- Example 20 - APC-AdFasL induces specific tolerance to adenovirus.
- T-cell tolerance induced by Ad/FasL expressing APCs is specific for adenoviral vector rather than a general immune suppression to viral infection
- APC-AdFasL and APC-AdControl tolerized mice to an irrelevant viral infection is measured.
- B6 +/+ mice are treated with APC-AdFasL as described above for induction of tolerance, and then challenged
- Example 21 - Fas ligand expressing adenovirus provides both systemic immune tolerance to Ad transfected APCs and confers privilege on cells that are transfected with the Ad/FasL- ⁇ Gal.
- APCs transfected with Fas ligand induce specific apoptosis and specific
- T-cell tolerance to antigens both in vitro and in vivo This is observed using a macrophage cell line derived from Fas-deficient C57BL/6(B6)-/pr//pr mice that are transiently transfected with Fas ligand, and then injected into mice of a different MHC.
- macrophages co-infected with Fas ligand and viral vector are highly efficient presenters of viral vector antigens and Fas ligand. This results in antigen-specific apoptosis of vector-reactive T-cells.
- Transfection of Fas ligand into a ⁇ -islet cell line also confers immune privilege on the host ⁇ -islet- reactive T-cells and prevention of diabetes where the vector is adenovirus.
- Example 22 - APCs transfected with Fas ligand induce apoptosis and specific T-cell tolerance to antigens in vitro and in vivo.
- An APC line derived by short-term culture of peritoneal macrophages from Fas mutant B6-lpr/lpr mice does not express Fas, but expressed MHC class II IA b ,
- FIG. 9c This cell line is transfected with a eukaryotic expression vector (pcDNAIII) containing the full-length murine Fas ligand and selected using G418.
- APCs transfected with Fas ligand APC-FL
- APC-CV APC-CV cells are capable of presenting alloantigen as the ⁇ -irradiated cells induced a prohferative responses in co-cultured splenic H-2 k T-cells (MRL-+/+ or MR -lpr/lpr) (Fig. 9e).
- APC-FasL cells are capable of presenting alloantigen and induce a prohferative response if the responding T-cells are obtained from MRL-lpr/lpr mice, which do not express Fas.
- presentation of antigen by APCs that express Fas ligand induces tolerance of the Fas-positive responding T-cells.
- Example 23 Induction of allogeneic T-cell tolerance by Fas ligand expressing APCs. 4-wk-old of MRL-+/+ and -Ipr/lpr mice are injected i.v. with macrophages
- splenic T-cells are isolated from treated mice and cultured under various stimulatory conditions.
- 5 x 10 5 T-cells are cultured with 2 x 10 5 ⁇ -irradiated total spleen cells from B6 +/+ mice (Fig. 10a).
- 5 x 10 5 T-cells are cultured with 2 x 10 5 ⁇ -irradiated total spleen cells from BALB/c mice (Fig.
- T-cell proliferation is determined by incorporation of [ 3 H]-thymidine at 24, 48, 72 and 96 hours.
- Example 24 Antigen-specific clonal deletion of the T-cells induced by Fas ligand expressing APCs in H-2D b /HY reactive TCR transgenic mice.
- TCR T-cell receptor
- CD4 CD8 " T-cells isolated from 5-month-old, female, B ⁇ -lpr/lpr mice are used as controls in which the HY antigen is not expressed.
- the Fas ligand activity of the CD4 " CD8 " T-cells is high and specific inhibition of this release by soluble Fas-Ig fusion protein (Fig. 1 lb). Alloantigen-specific T-cell tolerance was analyzed after i.v.
- T-cells from female, TCR transgenic +/+ mice treated with Fas ligand " HY 1" male cells exhibited a decreased prohferative response upon stimulation with either H-2D b /HY spleen cells or crosslinking with the M33 anti-clonotypic TCR antibody, but not anti-CD3.
- Fas ligand-positive cells derived from H-2D b female mice had no effect on the H-sD b HY reactivity of recipient T-cells in TCR transgenic female mice.
- Example 25 Tolerance induction due to Fas-mediated deletion of H-2D b /HY Reactive CD8 + T-cells.
- Clonal deletion of H-2D b /HY cells is examined by analyzing the numbers of H-2D b /HY reactive CD8 + T-cells in the female TCR transgenic mice using the anti-clonotypic mAb M33. Tolerance induction is carried out as described above and the numbers of M33 + CD8 ⁇ T-cells in the peripheral lymph node (Fig. 12a) and spleen (Fig. 12b) cells are determined. In untreated, female, transgenic +/+ and Ipr/lpr mice, approx.
- Fas ligand expressing APCs is associated with Fas ligand-mediated clonal deletion of antigen-specific T-cells that recognize the antigen presented by the APCs.
- Time-course analysis of the deletion of M33 + CD8 + T-cells in the spleen showed that the depletion commenced as early as 24 h after treatment in the female TCR transgenic +/+ mice that received Fas ligand-positive H-2D b /HY cells and continued during the 10-d period of the treatment.
- Fas-Ig effectively inhibited the deletion in the TCR transgenic +/+ mice, which further supports the role of Fas ligand expression on the APCs in clonal deletion.
- Fas expression also is analyzed in M33 + CD8 + PLN T-cells in the female TCR transgenic Ipr/lpr mice did not express Fas antigen regardless of treatment. Fas expression on M33 + CD8 T T-cells expressed low levels of Fas (14%), whereas additional treatment with Fas-Ig led to the majority of M33 + CD8 + T-cells are deleted by Fas ligand expressing APCs.
- Example 26 Inhibition of insulitis in NOD mice using a synegeic ⁇ -islet cell line that expresses Fas ligand to induce T-cell tolerance.
- NIT-1 The syngeneic ⁇ cell line, NIT-1, is used as the APC for Fas ligand expression. NIT-1 cells do not express Fas antigen and do not undergo either anti-Fas antibody or Fas ligand mediated apoptosis (data not shown). This cell line is transfected with an expression vector containing Fas ligand mediated apoptosis (data not shown). This cell ine is transfected with an expression vector containing Fas ligand (pcDNAIII) as described in Example 9. Fas ligand transfected, but not control, cells expressed functional Fas ligand (Fig. 13a).
- NIT-1 cells There are increased T-cell prohferative and cytotoxic responses in
- NOD mice treated with control NIT-1 cells (Fig. 13b,c).
- NOD mice treated with Fas ligand expressing NIT-1 cells only exhibit a minimal increase in response compared with the untreated control. 100% of NOD mice that received no treatment or treatment with NIT-l/CV developed insulitis, and 100% of islets from each individual mouse are involved. In contrast, only 1 of 3 mice receiving
- NIT-1 /FasL developed minor insulitis, with only 10% of islets involved (Fig. 14).
- Example 27 Inhibition of Insulitis in Nod mice using NIT-1 - AdFasL as a syngenic ⁇ islet cell to induce T-cell tolerance to an Ad vector.
- Example 25 The procedure of Example 25 is repeated with the expression vector of
- Example 14 substituted therein.
- NIT-1 - Ad control treated mice develop insulitis involving 100% of islet cells of individual mice.
- NIT-1 - AdFasL treated mice did not develop insulitis.
- Example 28 Transfection with Fas ligand and adenovirus results in high expression of ⁇ -Gal in macrophages.
- the polylysine method is used for targeting Fas ligand and Ad to APC via the receptor-mediated endocytosis pathway (49-51, 68, 69). It is important to link Ad to molecular conjugates, and at the same time preserve both the binding and endosome disruption capabilities of the virus.
- the linkage is accomplished by conjugating a molecular antibody against a foreign epitope on the adenovirus hexon protein to the polylysine-protein complex.
- a chimeric adenovirus containing a foreign epitope in the surface region of its hexon protein is constructed.
- the loop region of the hexon protein is a useful foreign epitope expression region.
- Example 29 Creation of an immune-privileged site for prolonged expression of the adenovirus gene product using co-expression of FasL and adenovirus in muscle.
- 10 9 adenovirus is co-injected into mouse muscle tissue with 5 ⁇ g of purified FasL DNA under the regulation of the CMV promoter (pFasL), or with identical control plasmid DNA which does not express Fas ligand.
- FasL production by adenovirus confers a high level of specific immunity to the adenovirus, prevent immune elimination of cells expressing the adenovirus, and result in prolonged expression of the adenovirus gene product.
- Example 30 Modification of viral tropism to allow high efficiency targeting to macrophages.
- Ad/FasL in addition to the in vitro infection and tolerance induction by Ad/FasL, in vivo infection by an Ad/FasL virus is operative.
- a FasL Tg mouse which overexpresses FasL specifically in T-cells without cytotoxicity is used (70).
- Similar techniques direct Ad/FasL for high transfection of APCs in vivo (macrophages) by targeting adenovirus to the macrophage mannose receptor. This is accomplished using a synthetic molecular conjugate consisting of a mannosylated polylysine protein combined with the adenovirus fiber/knob protein.
- a mannosylated polylysine has been demonstrated to bind to the macrophage mannose receptor and lead to high efficiency transfection of DNA complexes into islet cells (71, 72).
- Modification of adenovirus tropism uses the methods detailed in U.S. Provisional Patent Application 60/054,112 for modification of the adenovirus knob/fiber protein to include a 10 amino acid polypeptide capable of binding E-selectin and targeting adenovirus to inflamed sites in the synovium and also using an anti-adenovirus sFv/TL-2 fusion protein to direct adenovirus tropism to T-cells.
- Example 31 Production of an adenovirus-infected, Fas ligand expressing macrophage for induction of tolerance to adenovirus.
- the APC line of Example 22 expresses high level of MHC class I and II antigen, B7 and Fas ligand. This macrophage cell line express high levels of H-
- This cell lines does not express Fas, exhibits low levels of Fas ligand activity, and has been transfected with a CMV promoter/FasL construct to produce a stable transfected macrophage cell line which expresses FasL.
- This cell line can also be infected with Ad by known techniques to allow expression of adenovirus antigens and gene products.
- Example 32 Analysis of Tolerance to Ad/Fas Ligand.
- Tolerance to adenovirus will analyzed using a macrophage cell line that stably expresses Fas ligand (APC-FL) such as that of Example 22 and are infected with the adenovirus by intravenous (i.v.) or intranasal (i.n.) injection to induce tolerance. Tolerance is analyzed at d 2, 7, 14, 28, and 56 h after injection of 5 x 10 6 Ad-APC-FL. Mice are bled by retro-orbital sinus puncture for analysis of antibody titer to adenovirus.
- APC-FL Fas ligand
- T-cells tolerance are evaluated by [ 3 H]-thymidine incorporation to measure the T-cell prohferative response, BrdU incorporation, and flow cytometric analysis of BrdU-positive T-cells to determine the frequency of prohferative T-cells, and 7AAD three color flow cytometric analysis to determine apoptosis of the T-cells.
- the level of IL-2 in the culture supernatants is also measured to determine T-cell activation.
- a similar technique is used to test to determine if cytotoxic CD8 + T- cells are toleralized or deleted from the spleen in vivo. The CD8 + T-cells are tested for their ability to lyse chromium-labeled Ad-APC.
- T-cells are isolated as described in reference to Fig. 10.
- a suitable effector: target (E:T) ratio of CD8 + T-cells to chromium-labeled, adenovirus-pulsed macrophage target cells is thereby obtained.
- E:T target
- Example 34 Construction of an adenovirus producing Fas ligand.
- a full length 1114bp murine Fas ligand cDNA clone is obtained by conventional methods (73-75).
- this Fas ligand clone is used to produce the Ad/FasL vector (Fig. 16).
- this clone has undergone recombination with the adenovirus genome in 293 cells. This construct and variations of this construct are used in the present invention.
- the Fas ligand cDNA clone is introduced into the p ⁇ Elsplb shuttle vector. To produce recombinant adenovirus, this DNA is co-transfected into weakly Fas + 293 cells.
- transfections are carried out using 3 different transfection methods including: lipofectin, dotap, and the calcium chloride precipitation method.
- lipofectin the majority of the transfected 293 cells undergo apoptosis within 24 h, whereas minimal apoptosis occurs after transfection of 293 cells with the control shuttle vector.
- Example 35 Production of p ⁇ ElsplBloxp/FasL:.
- AdLOXP/FasL recombinant virus A Fas ligand expressing recombinant adenovirus, denoted as AdLOXP/FasL recombinant virus is shown in Fig. 17.
- the p ⁇ ElsplBloxp/Fas shuttle vector is co-transfected with pJM17 to produce the AdLOXP/FasL.
- the AdLOXP/FasL is co-infected with the Ad/CRE recombinant adenovirus.
- the CRE excises the LOXP sites placing FasL under the control of the CMV promoter resulting in high levels of expression of FasL.
- AdLOXP/FasL does not induce toxicity in the 293 cells.
- the AdLOXP/FasL adenovirus is combined with the Ad/CRE recombinant adenovirus.
- the CRE protein has been well studied and is demonstrated to be able to excise the LOXP sites which in the present invention construct results in the production of FasL under the CMV promoter. This system was first heavily utilized for production of transgenic mice. It has applied by several investigators for adenovirus recombination (73-75). These viruses can be co-infected into any cell, such as macrophages used herein with high efficiency.
- Macrophages are transfected with the recombinant adenovirus. Lac z expression is confirmed by ⁇ -galactosidase staining as described in Example 8.
- mice are analyzed at different time courses for expression of the lacZ marker gene in the lung and liver. Fas ligand expression is confirmed by ability of the transfected macrophages to induce apoptosis of 51 Cr labeled and Fas sensitive cell line A20 as per Example 5. These experiments are carried out with and without the presence of a soluble Fas (sFas) capable of neutralizing Fas ligand activity to demonstrate that cytotoxicity is specific for Fas ligand.
- sFas soluble Fas
- Example 37 Treatment of a lung disease with AdCF FasL transfected into APCs.
- the CF gene is ligated into the EcoRV site of the Ad shuttle vector of
- FIG 16 so as to be under the control of the regulatory element.
- the CF modified vector, Ad Shuttle CF is co-transfected with pJM17 to produce recombinant AdCF.
- FasL this is co-infected with the AdLOXP FasL and AxCanCre.
- These three viruses will be co-administered intra-nasally into the airways of 6 week old, female bleomycin - TPF mice.
- the mice are challenged with AdCF.
- the mice so treated are tolerant of the CF gene therapy vector 7 days after challenge.
- Example 38 Treatment of a lung disease with AdPI/FasL transfected into APCs.
- the protease inhibitor (PI) gene is ligated into the EcoRV site of the Ad shuttle vector of Figure 16 so as to be under the control of the regulatory element.
- the PI modified vector, Ad Shuttle PI is co-transfected with pJM17 to produce recombinant AdPI.
- FasL this is co-infected with the AdLOXP FasL and AxCanCre.
- Example 39 Treatment of hemophilia with AdF8/FasL transfected in APCs.
- the factor VIII gene is ligated into the EcoRV site of the pJM 17 vector of Figure 16 so as to be under the control of the regulatory element.
- the PI modified vector, Ad Shuttle Factor VLTJ is co-transfected with pJM 17 to produce recombinant Ad Factor VIII.
- FasL this is co-infected with the Ad LOXP FasL and AxCanCre.
- Example 40 Determine the expression of Fas ligand and Ad/ ⁇ -gal in vivo at different time points after infection in vivo in tolerized and non-tolerized mice.
- Detailed analysis of expression of Fas ligand RNA and protein, viral RNA and protein, and ⁇ -gal is carried out at different time point and under different conditions of tolerance induction involves analysis of tissue sections using immunohistochemical staining for Fas, ⁇ -Gal. Tissue sections are also analyzed for in-situ expression by RT-PCR and for apoptosis by the tunel method. The phenotype of T-cell and macrophages in lymphoid organs and lung is determined by flow cytometry analysis.
- Fas ligand expression by single cell suspension is determined by 1) Cr release assay of Fas apoptosis sensitive target cells, 2) frequency analysis by single cell Fas ligand PCR.
- Fas apoptosis signaling To abolish cell surface Fas expression, it is sufficient to prevent Fas apoptosis signaling, since it is well established that Fas expression does not necessarily correlate with Fas apoptosis signaling (76-81).
- the analysis of Fas- apoptosis signaling and inhibition of this by IL-l ⁇ converting enzyme family members and also inhibitors of HCP are useful in testing abolition. The will be accomplished by incorporating both Fas and known inhibitory proteins of Fas apoptosis into modified Ad virus.
- a specific construct capable of expressing Fas ligand safely and at the same time protect the Fas ligand expressing cell from autocrine-mediated apoptosis includes both FasL and fragments of IL-l ⁇ or repeats of the peptide sequence the CPP32/Yama inhibitor DEVD-CHO, the ICE inhibitor YVAD-CHO which inhibit ICE and CPP32 and prevent Fas-mediated apoptosis in different cells, and Crm A, which block the cas pase pathway (81).
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU75859/98A AU7585998A (en) | 1997-05-22 | 1998-05-22 | Controlling immune response to specific antigens |
US09/424,281 US6689605B1 (en) | 1997-05-22 | 1998-05-22 | Controlling immune response to specific antigens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4742697P | 1997-05-22 | 1997-05-22 | |
US60/047,426 | 1997-05-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/424,281 A-371-Of-International US6689605B1 (en) | 1997-05-22 | 1998-05-22 | Controlling immune response to specific antigens |
US10/776,119 Division US20040157792A1 (en) | 1997-05-22 | 2004-02-10 | Controlling immune response to specific antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998052615A1 WO1998052615A1 (en) | 1998-11-26 |
WO1998052615A9 true WO1998052615A9 (en) | 1999-04-01 |
Family
ID=21948905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/010381 WO1998052615A1 (en) | 1997-05-22 | 1998-05-22 | Controlling immune response to specific antigens |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7585998A (en) |
WO (1) | WO1998052615A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063406A2 (en) * | 1999-04-21 | 2000-10-26 | Genzyme Corporation | Adenoviral vectors having nucleic acids encoding immunomodulatory molecules |
EP1180156A1 (en) * | 1999-05-27 | 2002-02-20 | Genzyme Corporation | Methods for induction of tolerance to adenoviral vectors and transgene products |
JP2021533803A (en) * | 2018-08-24 | 2021-12-09 | ロックアネイビオ, インコーポレイテッド | FASL Immunomodulated Gene Therapy Composition and Usage |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585362A (en) * | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
DK0733103T3 (en) * | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Preparation of High Titers of Recombinant AAV Vectors |
-
1998
- 1998-05-22 WO PCT/US1998/010381 patent/WO1998052615A1/en active Application Filing
- 1998-05-22 AU AU75859/98A patent/AU7585998A/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Also Published As
Publication number | Publication date |
---|---|
WO1998052615A1 (en) | 1998-11-26 |
AU7585998A (en) | 1998-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4588296B2 (en) | Chimera vaccine | |
US20070172504A1 (en) | In vivo cell surface engineering | |
EP0551401B2 (en) | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity | |
KR101195400B1 (en) | Carcinoembryonic antigen fusions and uses thereof | |
US20030215427A1 (en) | CE7-specific redirected immune cells | |
ES2321246T3 (en) | NEW EXPRESSION VECTORS CONTAINING GENES OF ACCESSORY MOLECULAR BINDINGS AND THEIR USE FOR IMMUNOMODULATION AND TREATMENT OF EVIL TUMORS AND AUTOIMMUNE DISEASES. | |
US20100292309A1 (en) | Inducing immune-mediated tumor cell death | |
CN108070608B (en) | Chimeric antigen receptor targeting CD19-CD28-tEGFR and application thereof | |
NZ263550A (en) | Preparing cancer vaccines containing autologous tumour cells characterised in that tumour cells or firbroblasts are cultivated and transfected ex vivo with a composition of dna and a dna binding molecule conjugate | |
CN108864286B (en) | Chimeric antigen receptor targeting CD19, method for combined expression of anti-PD 1 antibody variable region and application thereof | |
JP2008507282A (en) | Specific inhibition of diseases related to autoimmunity and self-antigen | |
US20160317631A1 (en) | Increased t-cell tumor infiltration and eradication of metastases by mutant light | |
CA3031725A1 (en) | Lmp1-expressing cells and methods of use thereof | |
US7777004B2 (en) | Polypeptides comprising Fas activation and NKG2D-ligand domains | |
US6689605B1 (en) | Controlling immune response to specific antigens | |
WO2023217192A1 (en) | Preparation of chimeric antigen receptor immune cell constructed based on msln precursor protein and use thereof | |
WO1998052615A9 (en) | Controlling immune response to specific antigens | |
JP2003513619A (en) | Gene transfer vector for treating autoimmune diseases and diseases including immunopathogenesis | |
JP2023545241A (en) | Enhancement of immunity using chimeric CD40 ligands and coronavirus vaccines | |
JP2001521743A (en) | Method of inhibiting immune response to recombinant vector | |
US7064111B1 (en) | Use of soluble costimulatory factor for tumor immuno-gene therapy | |
WO2005017163A2 (en) | Phenotypic knockout of cell-surface proteins | |
Castro et al. | Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas | |
JP2002508976A (en) | Reduced immunogenic nucleotide expression system for use in gene therapy | |
EP4356970A1 (en) | Preparation and application of lox1-based chimeric antigen receptor immune cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-52 AND 54/57, DESCRIPTION, REPLACED BY NEW PAGES 1-48 AND 50-53; PAGE 53 RENUMBERED AS PAGE49; PAGES 58-65, CLAIMS, REPLACED BY NEW PAGES 54-60; PAGES 66-69, AMENDED CLAIMS, RENUMBERED AS PAGES 61-64; PAGES 1/17-17/17, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09424281 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998550621 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |